Senior Director, Clinical and Commercial Supply Chain
Remix Therapeutics
Senior Director, Clinical and Commercial Supply Chain
Remix Therapeutics
Biotech firm developing mRNA-degrading therapies
Remix Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of medicines that modulate RNA splicing to address the underlying biology of disease. Our lead program, REM-422, targets pre-mRNA splicing in oncology and represents a fundamentally differentiated approach to drug discovery. Headquartered in Watertown, MA, Remix is advancing its pipeline with the urgency and scientific rigor that patients deserve.
Position Summary:
We are seeking an experienced, strategic, resourceful and highly motivated Senior Director, Clinical and Commercial Supply Chain to lead end-to-end supply planning; operational launch readiness for Remix’s first commercial product, ensuring product availability, compliant distribution, and robust performance management.
Reporting to the Vice President, Technical Operations, this role is ideal for a seasoned biotech supply chain leader with deep clinical supply expertise, commercial launch experience, and the ability to step into a highly visible leadership role with immediate impact. This role requires an individual with demonstrated ability to operate effectively in a fast-paced and evolving environment, engage cross-functionally (Quality, CMC, Clinical, Commercial, Regulatory, Accounting/Finance, IT), and communicate clearly and proactively across internal and external stakeholders. The ideal candidate will be a collaborative leader and critical thinker who can operate with autonomy, manage complex drug supply chains, and translate clinical and commercial demand forecasts into actionable supply strategies.
Key Responsibilities:
Qualifications:
Salary Range
$230,000 - $281,000 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.
Biotech firm developing mRNA-degrading therapies
Remix Therapeutics develops medicines for rare diseases by using targeted degradation of mRNA with an oral small molecule. Its lead candidate REM 422 degrades messenger RNA to stop production of disease-causing proteins and is in Phase 1 trials for ACC and AML, with FDA Orphan Drug designation. The company funds R&D through grants, partnerships, and eventual commercialization, leveraging collaborations with larger pharma. Its goal is to deliver safe and effective medicines for rare cancers and genetic disorders by advancing REM 422 and expanding its portfolio to address unmet medical needs.
Explore more opportunities at Remix Therapeutics